Table 1.

FN rates in the main trials of association between chemotherapy and immunotherapy

Trial	Cancer type	Drugs	FN: chemotherapy+immunotherapy arm	FN: chemotherapy arm	G-CSF or GM-CSF use
KEYNOTE-407	NSCLC squamous	Pembrolizumab+carboplatin+(nab)-paclitaxel	5.4%	3.6%	Permitted as for guidelines
KEYNOTE-189	NSCLC non-squamous	Pembrolizumab+cis- or carboplatin+pemetrexed	5.7%	2.0%	Permitted as for guidelines
IMpower133	SCLC	Atezolizumab+carboplatin+etoposide	2.5%	4.4%	NA
KEYNOTE-048	HNSCC	Pembrolizumab+cis- or carboplatin+5-fluorouracil	6.2%	5.2%	Permitted as for guidelines
IMpassion130	Breast cancer	Atezolizumab+nab-paclitaxel	1.9%	2.2%	NA

FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HNSCC, head and neck squamous cell carcinoma; NA, not available; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.